Needham & Company Reiterates Buy Rating on Taysha Gene Therapies

Analysts maintain $10 price target on the gene therapy company's stock.

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Needham & Company LLC has reiterated its buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA), with a price target of $10. This comes after the company received several other ratings from analysts, including a 'strong-buy' from Raymond James and a 'sell' from Wall Street Zen. Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system.

Why it matters

Taysha Gene Therapies is a promising biotech company working on innovative gene therapies for rare neurological disorders. Analyst ratings and price targets can provide insight into the company's potential growth and investor sentiment, which is important for both the company and potential investors.

The details

Needham & Company reiterated its buy rating and $10 price target on Taysha Gene Therapies' stock. Other analysts have also weighed in, with Raymond James issuing a 'strong-buy' rating and $13 target, while Wall Street Zen downgraded the stock to a 'sell' rating. Taysha Gene Therapies is developing a pipeline of gene therapy candidates, including treatments for GM2 gangliosidoses, GM1 gangliosidosis, and aromatic L-amino acid decarboxylase (AADC) deficiency.

  • Needham & Company released its report on Tuesday morning.
  • Raymond James issued its 'strong-buy' rating and $13 target price on Tuesday, January 6th.
  • Wall Street Zen cut its rating to 'sell' on Saturday, January 3rd.

The players

Needham & Company LLC

An investment banking and asset management firm that provides research coverage on Taysha Gene Therapies.

Taysha Gene Therapies

A clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system.

Raymond James

A financial services firm that provides investment banking and asset management services.

Wall Street Zen

A financial research and analysis firm that covers Taysha Gene Therapies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.